The search for emerging markets is necessary part of growth strategy in IVD. This report provides an overview of developments in the in vitro diagnostics industry in the Middle East. This report provides an overview of developments in the in vitro diagnostics industry in the Middle East.
The countries covered are:
- United Arab Emirates (UAE)
The Middle East market for in vitro diagnostics is provided in U.S. dollars for the years 2017 – 2022. Also provided is company activities and market drivers.
The report covers six segments of the IVD market in the Middle East:
- Clinical Chemistry
- Point of Care (POC)
The next five to ten years will see moderate and gradual change in global in vitro diagnostic (IVD) product markets. While clinical lab medicine plays an integral role in healthcare and disease management, new testing is difficult to launch in a time of global economic instability and rising healthcare costs. On the supply side, labs are challenged to add new tests with little increase in financial and human resources.
IVD companies are casting their nets in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care.
Many Middle Eastern countries, such as Saudi Arabia, have identified investment in healthcare infrastructure as a priority, the goal to expand healthcare beyond cities and into desert communities; today roughly 16% of the population is represented by rural areas of the country.
The region's public sector has historically dominated the delivery of healthcare in the Middle East; however, recent activity from governments in the region approaching investors to expand the private sector in health care continues to be encouraging. This is a strategy to diversify and reduce some dependence on the petroleum industry as oil prices continue to be strained. Countries in the region need to create systems that empower the private sector to participate more deeply in the healthcare system. Growth in private sector participation will improve the quality of healthcare and access to it.
Some of the total IVD market growth derives from increased test usage in emerging countries. All of the major IVD companies have reported growth in Turkey and Saudi Arabia, considered two of the top seven emerging markets. These countries continue to invest in healthcare infrastructure and insurance coverage for a growing more affluent middle class.
This development requires increased investment in healthcare. This increased investment most often takes the form of government tenders, which remain a major source ofsupply for state-controlled labs and hospitals. Lifestyle change a more sedentary lifestyle resulting in rising obesity rates has brought about the emergence of “Western” diseases such as diabetes. There is growing demand in the region, therefore, for medical tests.